Law360 (August 6, 2018, 4:57 PM EDT) -- Pain Therapeutics Inc. and Durect Corp. said Monday that the U.S. Food and Drug Administration once again had refused to approve its opioid painkiller Remoxy ER, calling the agency's fourth decision to turn down the drug "bizarre" in light of the ongoing opioid crisis.
Pain Therapeutics said that the FDA had issued a complete response letter for Remoxy ER, an abuse-deterrent, extended-release form of oxycodone. In the letter, the FDA said that the data submitted in Pain Therapeutics' new drug application didn't support the conclusion that the drug's benefits outweighed its risks.
"This is a bizarre conclusion to reach, especially during...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!